tetano
Editor, Senior Moderator
Vaccine
. 2021 Jan 23;S0264-410X(20)31603-0.
doi: 10.1016/j.vaccine.2020.12.036. Online ahead of print.
Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review
Florian Colrat[SUP] 1 [/SUP], Edward Thommes[SUP] 2 [/SUP], Nathalie Largeron[SUP] 3 [/SUP], Fabi?n P Alvarez[SUP] 4 [/SUP]
Affiliations
Abstract
Introduction: Due to waning immunity, adults aged ≥65 years are at increased risk of seasonal influenza infection and its complications. Adding to this risk, older adults have reduced responses to influenza vaccines. A high-dose trivalent inactivated influenza vaccine (Fluzone High-Dose, Sanofi Pasteur) (IIV3-HD) was developed to improve protection against influenza in adults aged ≥65 years and has been licensed in the US since 2009 and in Canada since 2015. Post-licensure studies have shown that IIV3-HD is more effective than standard-dose trivalent inactivated influenza vaccine (IIV3-SD) at protecting against influenza infection in this population. Here, we performed a systematic review of economic analyses of IIV3-HD in adults aged ≥65 years.
Methods: On June 9, 2019, using the Ovid search platform, we searched Econlit, Embase, and Ovid MEDLINE? for original studies published in peer-reviewed journals examining the economics or cost-effectiveness of IIV3-HD in adults aged ≥65 years. Two reviewers independently selected studies and assessed their quality.
Results: Seven studies were selected, all performed in the US or Canada. Five studies were funded by IIV3-HD manufacturer, and the remaining two by the US National Institute of General Medical Sciences. In all studies, IIV3-HD reduces healthcare resource utilization and is cost-effective or cost-saving compared to IIV3-SD. The main driver is reduced hospitalizations for cardiorespiratory events.
Conclusion: IIV3-HD is cost-saving or cost-effective versus IIV3-SD in adults aged ≥65 years. Reduced cardiorespiratory complications are an important driver of these economic benefits. A video summary of the article can be accessed here https://shared-assets.adobe.com/link/9466d23c-3068-46b1-78ef-73df00610c78.
Keywords: Cost-effectiveness; Health economics; High-dose influenza vaccine; Systematic review.
. 2021 Jan 23;S0264-410X(20)31603-0.
doi: 10.1016/j.vaccine.2020.12.036. Online ahead of print.
Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review
Florian Colrat[SUP] 1 [/SUP], Edward Thommes[SUP] 2 [/SUP], Nathalie Largeron[SUP] 3 [/SUP], Fabi?n P Alvarez[SUP] 4 [/SUP]
Affiliations
- PMID: 33518466
- DOI: 10.1016/j.vaccine.2020.12.036
Abstract
Introduction: Due to waning immunity, adults aged ≥65 years are at increased risk of seasonal influenza infection and its complications. Adding to this risk, older adults have reduced responses to influenza vaccines. A high-dose trivalent inactivated influenza vaccine (Fluzone High-Dose, Sanofi Pasteur) (IIV3-HD) was developed to improve protection against influenza in adults aged ≥65 years and has been licensed in the US since 2009 and in Canada since 2015. Post-licensure studies have shown that IIV3-HD is more effective than standard-dose trivalent inactivated influenza vaccine (IIV3-SD) at protecting against influenza infection in this population. Here, we performed a systematic review of economic analyses of IIV3-HD in adults aged ≥65 years.
Methods: On June 9, 2019, using the Ovid search platform, we searched Econlit, Embase, and Ovid MEDLINE? for original studies published in peer-reviewed journals examining the economics or cost-effectiveness of IIV3-HD in adults aged ≥65 years. Two reviewers independently selected studies and assessed their quality.
Results: Seven studies were selected, all performed in the US or Canada. Five studies were funded by IIV3-HD manufacturer, and the remaining two by the US National Institute of General Medical Sciences. In all studies, IIV3-HD reduces healthcare resource utilization and is cost-effective or cost-saving compared to IIV3-SD. The main driver is reduced hospitalizations for cardiorespiratory events.
Conclusion: IIV3-HD is cost-saving or cost-effective versus IIV3-SD in adults aged ≥65 years. Reduced cardiorespiratory complications are an important driver of these economic benefits. A video summary of the article can be accessed here https://shared-assets.adobe.com/link/9466d23c-3068-46b1-78ef-73df00610c78.
Keywords: Cost-effectiveness; Health economics; High-dose influenza vaccine; Systematic review.